Shareholders might have noticed that Alkem Laboratories Limited (NSE:ALKEM) filed its quarterly result this time last week. The early response was not positive, with shares down 3.5% to ₹5,114 in the past week. It was a credible result overall, with revenues of ₹46b and statutory earnings per share of ₹56.48 both in line with analyst estimates, showing that Alkem Laboratories is executing in line with expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Alkem Laboratories after the latest results.
Following the latest results, Alkem Laboratories' 21 analysts are now forecasting revenues of ₹167.3b in 2027. This would be a satisfactory 7.0% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 7.5% to ₹186. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹166.9b and earnings per share (EPS) of ₹192 in 2027. The analysts seem to have become a little more negative on the business after the latest results, given the small dip in their earnings per share numbers for next year.
See our latest analysis for Alkem Laboratories
The consensus price target held steady at ₹5,975, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Alkem Laboratories analyst has a price target of ₹7,000 per share, while the most pessimistic values it at ₹4,589. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that Alkem Laboratories' rate of growth is expected to accelerate meaningfully, with the forecast 15% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 8.1% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. Alkem Laboratories is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Alkem Laboratories. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Alkem Laboratories analysts - going out to 2029, and you can see them free on our platform here.
That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Alkem Laboratories , and understanding this should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.